Pharmaceutical

A Leading Asian Pharmaceutical Company Launches GLP-1 Microneedle Daewoong Pharma Daewoong Therapeutics, a subsidiary of Daewoong Pharmaceutical, has launched CLOPAM®, an innovative GLP-1 microneedle platform designed to treat diabetes and obesity. This dissolvable microneedle patch offers pain-free drug delivery, reducing hospital visits and enhancing patient adherence.
Johnson & Johnson: Cuts 5 Pipelines, Including Neurology and Oncology Johnson & Johnson Johnson & Johnson's Q3 2024 report reveals major pipeline cuts, including mid-stage neurology and oncology programs. Despite positive results in Alzheimer's and depression treatments, the company halted key projects in Parkinson’s, bipolar disorder, and mantle cell lymphoma.
Pfizer's RSV Vaccine Shows 90% Efficacy Against Severe Respiratory Diseases Pfizer Pfizer's RSV vaccine, Abrysvo, shows 90% efficacy against severe respiratory illness in older adults, highlighting its potential as RSV cases rise. Despite CDC's narrower vaccination guidelines, Abrysvo remains a key product, nearing $1 billion in sales within seven months of FDA approval.
Many Seek Beauty: 380 Million Investment, Long-Lasting Botulinum Toxin Approved Botulinum toxin China has approved DAXXIFY® (RT002), a long-lasting botulinum toxin formulation by Sisram Medical Technology, for temporarily improving glabellar lines. Using patented Peptide Exchange Technology, this marks a significant advancement in neuromodulation.
Bluebird Bio Gene Therapy Linked to Blood Cancer Bluebird bio Bluebird Bio faces a dramatic fall in valuation after seven children develop blood cancer following treatment with its gene therapy, Skysona. Once valued at $30 billion, Bluebird now struggles below $1 billion.
Top 10 Key Readouts in Q4 2024 Drug Development Top 10 key clinical readouts in drug development for Q4 2024, spanning treatments for obesity, depression, Alzheimer's, pain, muscular atrophy, schizophrenia, and more. These updates involve a variety of drug modalities including monoclonal antibodies, CAR-T, proteins, and peptides.
FDA Approves Roche's PI3Kα Inhibitor - Doubled PFS! FDA Roche The FDA approved Genentech's PI3Kα inhibitor, Inavolisib (Itovebi), in combination with palbociclib and fulvestrant for advanced breast cancer patients with PIK3CA mutations. The therapy showed a significant 57% reduction in disease progression in the Phase III INAVO120 trial.
Eli Lilly Leadership Changes Eli Lilly Eli Lilly announces major leadership changes, appointing Thomas J. Fuchs as its first Chief AI Officer, highlighting the company's commitment to AI-driven healthcare innovation. Additionally, Yan Qiong joins as VP of the Diabetes Business Unit, boosting growth in China's market.
Big Pharma to Shape the Future of Cell and Gene Therapy Catapult Matthew Durdy, CEO of Cell and Gene Therapy Catapult, led a panel at the 2024 MESA Conference alongside pharma leaders from Pfizer, Bayer, BMS, and Eli Lilly. They discussed Big Pharma's growing role in the cell and gene therapy sector, addressing commercialization challenges.
Victory! FDA Approves Pfizer's Hemophilia A or B Antibody Drug Marstacimab Pfizer FDA approves Pfizer’s new hemophilia drug, marstacimab (Hympavzi), for preventing bleeding episodes in patients with hemophilia A or B. The once-weekly therapy, priced at $795,600 per year, offers moderate improvements and aims to capture market share through its convenience.